[Experimental study of interleukin-12 gene vaccines in the treatment of low-load malignant lymphoma (EL4)].
OBJECTIVE
Two kinds of murine interleukin-12 (mIL-12) fusion gene vaccines were used to treat the murine low-load malignant T cell lymphoma EL4 as minimal residual disease (MRD) model.


METHODS
C57BL/6 synergistical mice were subcutaneously inoculated with 1 x 10(6) wild-type (wt) EL4 tumor cells as low-load lymphoma model treated with two mIL-12 gene vaccines. Package cell line PA317/12 producing mIL-12 retrovirus (RV) was used as in vivo vaccine and EL4 tumor cells transferred with mIL-12 gene as ex vivo vaccine.


RESULTS
In both mIL-12 gene vaccine-treated groups, there was no tumor growth in 50% mice 60 days after inoculation. Nine of these no tumor growth mice were re-challenged with 5 x 10(5) wt EL4 cells, and 5 of them survived without tumors in another 60 days. All control mice died with tumors within one month after inoculation. Among those developed tumors in both vaccine-treated groups, the development of tumors was delayed, the survival period prolonged (P < 0.01), and the tumors size at death smaller (P < 0.05) as compared with the controls. In the long-survived vaccine-treated mice, no residual tumor cells were found by morphological examination.


CONCLUSIONS
Both IL-12 gene vaccines can efficiently eliminate wt EL4 MRD in C57BL/6 mice.
Jiang
Q
Q
Department of Hematology, Lanzhou General Hospital, Lanzhou 730050, China.
Da
W
W
Ou
Y
Y
D000818:Animals; D002460:Cell Line; D004195:Disease Models, Animal; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D007376:Interleukin-2 / Q000235:genetics / Q000627:therapeutic use*; D008223:Lymphoma / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D018365:Neoplasm, Residual / Q000401:mortality / Q000628:therapy; D012190:Retroviridae / Q000235:genetics; D019444:Vaccines, DNA / Q000627:therapeutic use*
D007376:Interleukin-2; D019444:Vaccines, DNA